Objective To observe the clinical effect of glimepiride combined with metformin and liraglutide in treating type 2 diabetes mellitus patients merged with hyperlipidaemia.Methods A total of 108 type 2 diabetes mellitus patients merged with hyperlipidaemia were selected in the Third People's Hospital of Huizhou from September 2014 to January 2016,and they were divided into control group and observation group according to random number table,each of 54 cases.Patients of control group received glimepiride combined with metformin,while patients of observation group received extra liraglutide based on that of control group;both groups continuously treated for 16 weeks.Blood lipids index,blood glucose related index,index of cardiac function before and after treatment were compared between the two groups,and incidence of adverse reactions was observed during the treatment.Results No statistically significant differences of TC,TG,HDL-C or LDL-C was found between the two groups before treatment (P ＞ 0.05);after treatment,TC,TG and LDL-C of observation group were statistically significantly lower than those of control group,while HDL-C of observation group was statistically significantly higher than that of control group (P ＜ 0.05).No statistically significant differences of FPG,2 h PG or HbA1c was found between the two groups before treatment (P ＞0.05),while FPG,2 h PG and HbA1c of observation group were statistically significantly lower than those of control group (P ＜ 0.05).No statistically significant differences of LVEF,LVEDD,serum NT-proBNP level or 6-minute walking distance was found between the two groups before treatment (P ＞ 0.05);after treatment,LVEF of observation group was statistically significantly higher than that of control group,LVEDD of observation group was statistically significantly shorter than that of control group,serum NT-proBNP level of observation group was statistically significantly lower than that of control group,while 6 -minute walking distance of observation group was statistically significantly longer than that of control group (P ＜ 0.05).No statistically significant differences of incidence of adverse reactions was found between the two groups during the treatment (P ＞ 0.05).Conclusion Glimepiride combined with metformin and liraglutide has certain clinical effect in treating type 2 diabetes mellitus patients merged with hyperlipidaemia,can effectively adjust the blood lipid metabolism,reduce the blood glucose,improve the cardiac function,with relatively high safety.%目的 观察格列美脲与二甲双胍联合利拉鲁肽治疗2型糖尿病合并高脂血症患者的临床疗效.方法 选取2014年9月—2016年1月惠州市第三人民医院收治的2型糖尿病合并高脂血症患者108例,采用随机数字表法分为对照组和观察组,每组54例.对照组患者予以格列美脲与二甲双胍治疗,观察组患者在对照组基础上加用利拉鲁肽治疗;两组患者均连续治疗16周.比较两组患者治疗前后血脂指标、血糖指标、心功能指标,并观察两组患者治疗期间不良反应发生情况.结果 治疗前两组患者总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)水平比较,差异无统计学意义(P＞0.05);治疗后观察组患者TC、TG、LDL-C水平低于对照组,HDL-C水平高于对照组(P＜0.05).治疗前两组患者空腹血糖(FPG)、餐后2h血糖(2 h PG)、糖化血红蛋白(HbA1c)水平比较,差异无统计学意义(P＞0.05);治疗后观察组患者FPG、2hPG、HbA1c水平低于对照组(P＜0.05).治疗前两组患者左心室射血分数(LVEF)、左心室舒张末期内径(LVEDD)、血清N末端B型脑钠肽前体(NT-proBNP)水平、6 min步行距离比较,差异无统计学意义(P＞0.05);治疗后观察组患者LVEF高于对照组,LVEDD小于对照组,血清NT-proBNP水平低于对照组,6 min步行距离长于对照组(P＜0.05).两组患者治疗期间不良反应发生率比较,差异无统计学意义(P＞0.05).结论 格列美脲与二甲双胍联合利拉鲁肽治疗2型糖尿病合并高脂血症患者的临床疗效确切,可有效调节患者血脂代谢,降低患者血糖,改善患者心功能,且安全性较高.
展开▼
